Case Report: Metastatic colorectal cancer with ALK–CEP44 fusion and rapid resistance development
ALK-targeted therapy may provide benefit in selected CRC cases with atypical <i>ALK</i> alterations, even when the oncogenic role is uncertain. Comprehensive molecular profiling and timely therapeutic decisions are essential in managing such rare and complex cases.
Authors
- Andreas N. WICKI (ORCID: https://orcid.org/0000-0002-2924-8080)
- Martin Zoche (ORCID: https://orcid.org/0000-0002-0421-7229)
- Tarun Mehra
- Silke Potthast
- Silvan Hofmann
- Claudine Egger
Institutions
- University Hospital of Zurich (CH)
- Spital Limmattal (CH)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-06-18
- DOI
- https://doi.org/10.3389/fonc.2025.1613235
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00